Table 2. Characteristics of studies included in themeta-analysis of DAPK promoter methylation and clinicopathological features.
| Author | Year | Region | Method# | Sex | Smoking | Alcohol | N_stage* | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Male (M/U) | Female (M/U) | Smoker (M/U) | Non-smoker (M/U) | Yes (M/U) | No (M/U) | N0 (M/U) | N+ (M/U) | ||||
| Misawa, K.[34] | 2016 | Japan | QMSP | 54/55 | 17/7 | 53/42 | 18/20 | 51/36 | 20/26 | 31/28 | 31/28 |
| Arantes, L. M.[21] | 2015 | Brazil | QMSP | 29/7 | 3/1 | 26/3 | 6/5 | 22/4 | 10/4 | 9/2 | 23/6 |
| Pierini, S.[35] | 2014 | Bulgaria | MS-HRM | 37/54 | 4/2 | 28/44 | 13/12 | 29/43 | 12/13 | ||
| Wong, Y.K.[26] | 2011 | Taiwan | MSP | 25/33 | 4/2 | 20/30 | 7/7 | 18/22 | 5/9 | ||
| Su, P. F.[28] | 2010 | Taiwan | QMSP | 12/17 | 2/2 | 11/13 | 3/5 | 8/9 | 3/8 | 5/6 | 9/13 |
| Supic, G.[36] | 2009 | Serbia | MSP | 25/39 | 3/10 | 22/39 | 6/10 | 4/12 | 24/37 | ||
| Kulkarni, V.[33] | 2004 | India | MSP | 29/15 | 12/4 | 22/10 | 19/9 | ||||
M: DAPK promoter methylated, U: DAPK promoter unmethylated
#: MSP: methylation-specific polymerase chain reaction, QMSP: real-time quantitative MSP, MS_HRM: Methylation-sensitive high resolution melting
*: N_stage: lymph node invasion